Bayer’s Zieler On The Power Of Real World Data, Asia Pacific Outlook

Claus Zieler, senior vice president and head of commercial operations, Bayer pharmaceuticals division Asia Pacific, tells Scrip why real world data is “very powerful” as more stakeholders including physicians look beyond just randomized clinical trial data. Zieler also underscores the German multinational’s intent to give “special attention” to the fast-growing Asia Pacific region.

The Asia Pacific (APAC) is a significant contributor to Bayer AG ’s pharmaceutical earnings and Claus Zieler, senior vice president and head of commercial operations, Bayer pharmaceuticals division Asia Pacific, indicates that the German multinational is keen to sustain the momentum in the region. He maintains an upbeat tenor for a basket of products including Xarelto (rivaroxaban) and Eylea (aflibercept), for which Bayer recently ramped up its sales expectations, but prefers not to be drawn into specifics on any potential headwinds in the region as a result of the emerging geopolitical situation.

In an interview with Scrip in Singapore last month, Zieler also underscored the value of real world data in the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By 

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.

Finance Watch: Scorpion Spinout Antares Launches With $177m For Precision Medicines

 
• By 

Private Company Edition: Antares’ lead asset will enter the clinic in 2026 after Lilly committed up to $2.5bn for Scorpion’s Phase I/II PI3Kα inhibitor STX-478. Also, Amplify raised $200m for its first biotech VC fund and Mosanna raised an $80m series A round, among other financings.

UCB Follows Fellow European Pharmas With Major US Investment

 
• By 

The Belgian drugmaker is boosting its biologics capacity over the pond.

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

More from Scrip

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Executives On The Move: New CMOs At Instil Bio, Nkarta & Catalyst Pharma

Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.